Type 1 Diabetes Trial, Recruiting NCT03512132 Sponsor: Centre Hospitalier Universitaire Dijon Condition: Type 1 Diabetes
Back to Type 1 Diabetes

Type 1 Diabetes Trial, Recruiting

NCT03512132
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

This trial has four separate groups. People may be considered for one of the following groups:

Control Group (no diabetes):

  • Adults over 18 years old who have given oral consent
  • People who do not have diabetes
  • People with a fasting blood sugar level below 6.10 mmol/L
  • People with triglyceride (a type of blood fat) levels below 1.7 mmol/L
  • People with HDL ("good") cholesterol above 1.30 mmol/L for women, or above 1.03 mmol/L for men
  • People with kidneys functioning at a rate above 90 mL/min/1.73m²

Type 1 Diabetes Group with Normal Protein Levels in Urine:

  • Adults over 18 years old who have given oral consent
  • People with Type 1 diabetes (confirmed by medical history, a specific antibody test, or a low C-peptide level in the blood)
  • People with an HbA1c (average blood sugar measure) between 6% and 9%
  • People with normal amounts of a protein called albumin in their urine
  • People with kidneys functioning at a rate above 90 mL/min/1.73m²

Type 1 Diabetes Group with Mildly Elevated Protein in Urine (microalbuminuria):

  • Adults over 18 years old who have given oral consent
  • People with Type 1 diabetes (confirmed by medical history, a specific antibody test, or a low C-peptide level in the blood)
  • People with an HbA1c between 6% and 9%
  • People with mildly elevated levels of albumin protein in their urine, within a specific range
  • People with kidneys functioning at a rate above 90 mL/min/1.73m²

Type 1 Diabetes Group with High Protein in Urine (macroalbuminuria):

  • Adults over 18 years old who have given oral consent
  • People with Type 1 diabetes (confirmed by medical history, a specific antibody test, or a low C-peptide level in the blood)
  • People with an HbA1c between 6% and 9%
  • People with high levels of albumin protein in their urine (albumin-to-creatinine ratio above 30 mg/mmol)
  • People with kidneys functioning at a rate above 45 mL/min/1.73m²

Who may not be able to join:

  • People who are legally classified as a "protected adult" under the law (confirm with trial site)
  • People who are not enrolled in a social security scheme
  • Women who are pregnant or breastfeeding
  • People taking certain medications that affect fat metabolism, other than insulin — this includes cholesterol-lowering drugs (for the mildly elevated urine protein group only), corticosteroids, combined hormone contraceptives, retinoic acid, or antiprotease drugs
  • People with a Body Mass Index (BMI) over 30 kg/m² (a common measure of body weight relative to height)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Centre Hospitalier Universitaire Dijon
Registry
ClinicalTrials.gov
Start date
24 April 2018
Est. completion
1 April 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Ability to induce cholesterol efflux; Nitric oxide synthesis; Anti-inflammatory effect

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov